ProSciento Expands Executive Scientific Leadership, Appoints Dr. Julio Gutierrez as Vice President of Clinical Research and Clinical Science

SAN DIEGO, July 8, 2021 – ProSciento, Inc., a specialty clinical research organization (CRO) focused exclusively on diabetes, obesity, non-alcoholic steatohepatitis (NASH), and related metabolic diseases, announces the appointment of Julio Gutierrez, M.D., as Vice President of Clinical Research and Clinical Science.  Dr. Gutierrez, a board-certified physician in obesity medicine, transplant hepatology, and gastroenterology, is a renowned specialist in metabolic clinical research and patient treatment for liver diseases. In this role, Dr. Gutierrez will lead the company’s clinical science team.

“We’re thrilled to have Julio join our scientific leadership team.  With his deep knowledge of medical research, therapeutic development, and treatment modalities for metabolic diseases, as well as his work for ProSciento as a scientific consultant and principal investigator in early phase NASH clinical trials, he is already making key contributions within our expanding clinical science team,” said Marcus Hompesch, M.D., CEO, and Chairman of the Board. “In addition to his experience and scientific acumen, Julio has an extraordinary ability to articulate science, whether speaking with our clients, peers in the field, or with patients newly diagnosed. He also has a passion for ensuring under-represented patient communities have opportunities to participate in clinical research, which is particularly important as the prevalence of metabolic diseases continues to increase.”

“ProSciento is an industry leader in combining clinical research and scientific services for metabolic disease drug and device development and a driving force in developing new, critically needed strategies and methods to address patient access and therapeutic development for NASH. Their long-standing scientific expertise, including more early phase clinical trials in type 1 and type 2 diabetes than any other US provider, is widely recognized in the biopharmaceutical industry,” said Dr. Gutierrez. “ProSciento’s efforts to drive drug development in the field of fatty liver disease with its NASH PASS program will allow us to not only speed clinical development of much-needed therapeutics, but also to increase access to clinical trials amongst underrepresented populations. It’s a privilege to join the ProSciento team of highly respected scientists, physicians, and clinical development specialists and to help continue to make considerable contributions in expanding and improving therapeutic options for NASH, diabetes, obesity, and other related metabolic diseases.”

As an outstanding subject matter expert on NAFLD, NASH, and metabolic-related research, Dr. Gutierrez is an internationally recognized clinical researcher and has published more than 90 peer-reviewed publications on liver disease. Dr. Gutierrez is a transplant hepatologist and liver cancer specialist with an active practice in Southern California. He is also the former Medical Director of Liver Transplant at St. Vincent Medical Center in Los Angeles and an Adjunct Assistant Professor at the University of California, San Diego. Earlier in this career, he was a transplant hepatologist for Sharp Healthcare and the Director of Hepatobiliary Cancer at the Texas Liver Institute, where he participated in the landmark hepatitis C virus clinical trials studying oral combinations of Direct Acting Antivirals (DAAs).

Dr. Gutierrez earned his Medical Degree from Mount Sinai School of Medicine in New York City and completed his internship, residency, and fellowship at the University of California, San Diego.  He also completed a fellowship at the University of Miami School of Medicine.

About ProSciento, Inc.

ProSciento is the leading specialized clinical research organization (CRO) focused on NASH, diabetes, obesity, and related metabolic diseases. ProSciento works with biopharma companies worldwide to support their outsourced clinical research needs with comprehensive and customized services for multinational, early development clinical trial programs. Founded in 2003, ProSciento has conducted more than 325 clinical studies for diabetes, NASH, and obesity, and has contributed to the development of numerous approved metabolic drugs and devices on the global marketplace. For more information, please visit

For business development inquiries, please contact:

For media inquiries, please contact:
Abby Devine
Senior Director, Corporate Communications, ProSciento, Inc.

For clinical trial enrollment inquires, please contact:
Tel: +1 (866) 308-7427